PURPOSE: Mutations in the elongation of very long chain fatty acids 4 (ELOVL4) gene cause human Stargardt's macular dystrophy 3 (STGD3), a juvenile onset dominant form of macular degeneration. To understand the role of the ELOVL4 protein in retinal function, several mouse models have been developed by using transgenic (TG), knock-in (Elovl4(+/mut)), and knockout (Elovl4(+/-)) approaches. Here we analyzed quantitatively the ELOVL4 protein and its enzymatic products (very long chain saturated fatty acid [VLC-FA] and VLC-polyunsaturated fatty acid [VLC-PUFA]) in the retinas of 8 to 10-week-old TG1(+), TG2(+), and Elovl4(+/mut) mice that harbor the mutant ELOVL4 and compared them to their wild-type littermates and Elovl4(+/-) that do not express the mutant protein. We also analyzed skin from these mice to gain insight into the pathogenesis resulting from the ELOVL4 mutation. METHODS: ELOVL4 protein localization in the retina was determined by immunohistochemistry. Levels of wild-type ELOVL4 protein in skin and retinas were determined by Western blotting. Total lipids from skin and retinas were measured by gas chromatography-mass spectrometry (GC-MS). Retinal glycerophosphatidylcholines (PC) were analyzed by tandem mass spectrometry. RESULTS: Immunohistochemical and Western analysis indicated that wild-type ELOVL4 protein was reduced in heterozygous Elovl4(+/mut) and Elovl4(+/-) retinas, but not in TG2(+) retinas. We found that VLC-FA was reduced by 50% in the skin of Elovl4(+/-) and by 60% to 65% in Elovl4(+/mut). We found VLC-PUFA levels at ∼ 50% in both the retinas, and wild-type levels of VLC-PUFA in TG2(+) retinas. CONCLUSIONS: We conclude that the presence of the mutant ELOVL4 does not affect the function of wild-type ELOVL4 in the fully developed 8- to 10-week-old retinas.
PURPOSE: Mutations in the elongation of very long chain fatty acids 4 (ELOVL4) gene cause humanStargardt's macular dystrophy 3 (STGD3), a juvenile onset dominant form of macular degeneration. To understand the role of the ELOVL4 protein in retinal function, several mouse models have been developed by using transgenic (TG), knock-in (Elovl4(+/mut)), and knockout (Elovl4(+/-)) approaches. Here we analyzed quantitatively the ELOVL4 protein and its enzymatic products (very long chain saturated fatty acid [VLC-FA] and VLC-polyunsaturated fatty acid [VLC-PUFA]) in the retinas of 8 to 10-week-old TG1(+), TG2(+), and Elovl4(+/mut) mice that harbor the mutant ELOVL4 and compared them to their wild-type littermates and Elovl4(+/-) that do not express the mutant protein. We also analyzed skin from these mice to gain insight into the pathogenesis resulting from the ELOVL4 mutation. METHODS:ELOVL4 protein localization in the retina was determined by immunohistochemistry. Levels of wild-type ELOVL4 protein in skin and retinas were determined by Western blotting. Total lipids from skin and retinas were measured by gas chromatography-mass spectrometry (GC-MS). Retinal glycerophosphatidylcholines (PC) were analyzed by tandem mass spectrometry. RESULTS: Immunohistochemical and Western analysis indicated that wild-type ELOVL4 protein was reduced in heterozygous Elovl4(+/mut) and Elovl4(+/-) retinas, but not in TG2(+) retinas. We found that VLC-FA was reduced by 50% in the skin of Elovl4(+/-) and by 60% to 65% in Elovl4(+/mut). We found VLC-PUFA levels at ∼ 50% in both the retinas, and wild-type levels of VLC-PUFA in TG2(+) retinas. CONCLUSIONS: We conclude that the presence of the mutant ELOVL4 does not affect the function of wild-type ELOVL4 in the fully developed 8- to 10-week-old retinas.
Authors: Md Nawajes A Mandal; Rajesh Ambasudhan; Paul W Wong; Philip J Gage; Paul A Sieving; Radha Ayyagari Journal: Genomics Date: 2004-04 Impact factor: 5.736
Authors: P S Bernstein; J Tammur; N Singh; A Hutchinson; M Dixon; C M Pappas; N A Zabriskie; K Zhang; K Petrukhin; M Leppert; R Allikmets Journal: Invest Ophthalmol Vis Sci Date: 2001-12 Impact factor: 4.799
Authors: K Zhang; M Kniazeva; M Han; W Li; Z Yu; Z Yang; Y Li; M L Metzker; R Allikmets; D J Zack; L E Kakuk; P S Lagali; P W Wong; I M MacDonald; P A Sieving; D J Figueroa; C P Austin; R J Gould; R Ayyagari; K Petrukhin Journal: Nat Genet Date: 2001-01 Impact factor: 38.330
Authors: Robert E Anderson; Maureen B Maude; Mark McClellan; Michael T Matthes; Douglas Yasumura; Matthew M LaVail Journal: Mol Vis Date: 2002-09-23 Impact factor: 2.367
Authors: Sreemathi Logan; Martin-Paul Agbaga; Michael D Chan; Nabila Kabir; Nawajes A Mandal; Richard S Brush; Robert E Anderson Journal: Proc Natl Acad Sci U S A Date: 2013-03-18 Impact factor: 11.205
Authors: Pamela S Lagali; Jiafan Liu; Rajesh Ambasudhan; Laura E Kakuk; Steven L Bernstein; Gail M Seigel; Paul W Wong; Radha Ayyagari Journal: Invest Ophthalmol Vis Sci Date: 2003-07 Impact factor: 4.799
Authors: Rajesh Ambasudhan; XiaoFei Wang; Monica M Jablonski; Debra A Thompson; Pamela S Lagali; Paul W Wong; Paul A Sieving; Radha Ayyagari Journal: Genomics Date: 2004-04 Impact factor: 5.736
Authors: Julian Esteve-Rudd; Roni A Hazim; Tanja Diemer; Antonio E Paniagua; Stefanie Volland; Ankita Umapathy; David S Williams Journal: Proc Natl Acad Sci U S A Date: 2018-05-07 Impact factor: 11.205
Authors: Raghavendra Y Nagaraja; David M Sherry; Jennifer L Fessler; Megan A Stiles; Feng Li; Karanpreet Multani; Albert Orock; Mohiuddin Ahmad; Richard S Brush; Robert E Anderson; Martin-Paul Agbaga; Ferenc Deák Journal: Mol Neurobiol Date: 2021-07-05 Impact factor: 5.590